Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial
A Phase Ib study of the IL-2 variant immunocytokine cergutuzumab amunaleukin plus atezolizumab demonstrates manageable safety and robust peripheral immune activation but modest clinical activity in CEA-positive advanced solid tumors.
